Status:
UNKNOWN
Early Diagnosis of SCD Based on Radiogenomics
Lead Sponsor:
XuanwuH 2
Collaborating Sponsors:
University of Cologne
Conditions:
Alzheimer Disease
Subjective Cognitive Decline
Eligibility:
All Genders
60-79 years
Brief Summary
The incidence of AD dementia is increasing due to the aging population, putting a heavy burden on our society and economics. Exploring the mechanisms underlying SCD due to preclinical AD has scientifi...
Detailed Description
The overall prevalence of dementia worldwide is increasing, imposing a heavy burden on the public and health care systems. Subjective cognitive decline (SCD), characterized by a self-report of decline...
Eligibility Criteria
Inclusion
- 60-79 years old, right-handed and Mandarin-speaking subjects;
- self-experienced persistent decline in cognitive capacity in comparison with a previously normal status and unrelated to an acute event;
- normal age-, gender- and education-adjusted performance on standardised cognitive tests;
- concerns (worries) associated with memory complaint;
- failure to meet the criteria for MCI or dementia
Exclusion
- a history of stroke;
- major depression (Hamilton Depression Rating Scale score \> 24 points);
- other central nervous system diseases that may cause cognitive impairment, such as Parkinson's disease, tumors, encephalitis and epilepsy;
- cognitive impairment caused by traumatic brain injury;
- systemic diseases, such as thyroid dysfunction, syphilis and HIV;
- a history of psychosis or congenital mental growth retardation
Key Trial Info
Start Date :
January 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2025
Estimated Enrollment :
800 Patients enrolled
Trial Details
Trial ID
NCT04696315
Start Date
January 1 2021
End Date
December 31 2025
Last Update
September 8 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Neurolgy, Xuanwu Hospital of Capital Medical University
Beijing, Beijing Municipality, China, 100053